Glaxosmithkline Pharmaceuticals Ltd.

₹2,121.5

18.3 (0.9%)

GLAXO Share Price

Pharmaceuticals & Biotechnology

As on June 12, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 35,914 Cr

P/E Ratio34.69

Dividend Yield0.27 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	2,155.62	Bearish
10-DMA	2,168.3	Bearish
20-DMA	2,248.22	Bearish
50-DMA	2,340.39	Bearish
100-DMA	2,402.69	Bearish
200-DMA	2,516.56	Bearish

Historical Performance

1 Year

-36.1%

3 Years

52.9%

5 Years

39.8%

10 Years

21.3%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	38,217	37,492	34,537	32,517	32,780
Total Expenditure	25,125	25,718	25,450	24,474	25,162
Other Income	1,454	1,459	1,226	1,007	758
Operating Profit	14,546	13,233	10,313	9,049	8,377
Interest	27	13	18	18	20
Depreciation	664	668	697	658	682
Profit Before Tax	14,060	12,599	8,162	8,364	7,790
Consolidated Net Profit	10,360	9,276	5,900	6,107	16,947
Adjusted EPS	61	55	35	36	100

Compounded Sales Growth

10 Years:6.1

5 Years:5.5

3 Years:3.3

TTM:0.4

Compounded Profit Growth

10 Years:22.5

5 Years:23.7

3 Years:11.1

TTM:2.2

Stock Price CAGR

10 Years:1.9

5 Years:6.9

3 Years:15

TTM:-35.6

Return on Equity

10 Years:19.9

5 Years:100

3 Years:34.8

last year:61.2

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	1,694	1,694	1,694	1,694	1,694
Total Reserves	21,137	17,968	16,172	15,735	24,936
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	1,435	1,107	1,077	1,254	1,587
Other Current Liabilities	2,437	2,560	2,074	1,846	5,037
Short Term Borrowings	---	---	---	---	---
Total Liabilities	41,900	39,672	34,103	31,930	45,201
Capital Work in Progress	329	143	139	203	305
Long Term Loans & Advances	2,690	2,589	2,754	3,474	4,455
Currents Investments	13,910	11,182	8,132	5,183	3,656
Short Term Loans and Advances	365	264	247	122	284
Total Current Assets	36,062	34,099	27,984	24,943	37,079
Total Assets	41,900	39,672	34,103	31,930	45,201
Adjusted Book Value	135	116	105	103	157

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 34.69, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a moderate 3-year price CAGR of 15.0%, reflecting average market performance.
The stock carries a low beta of 0.7, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹14546 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹38217 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 643854.3

No. of Shares: 303 (Approx)

Performance:-35.6%

P/L: ₹-356145.7

NIFTY Performance: -4.4%

1 day Top Gainers